MedTrace Logo

101-PGC-005 for the Treatment of COVID-19

NCT05656521 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-05-30

No results posted yet for this study

Summary

This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of hospitalized patients with coronavirus disease (COVID-19).

Conditions

Interventions

DRUG

101-PGC-005

'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.

DRUG

Dexamethasone

Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.

Sponsors & Collaborators

  • 101 Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2023-04-21
Completion
2023-06-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656521 on ClinicalTrials.gov